Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Active, not recruiting · NCT05994235 · Registry updated 2026-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-02 | NCT05994235 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Epizyme, Inc. | 8 |
| Genentech, Inc. | 221 |
| Weill Medical College of Cornell University | 276 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Weill Cornell Medicine/NewYork-Presbyterian Hospital | New York | United States | 7 |